Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Ono Pharmaceutical is a mid-tier Japanese pharmaceutical company focused on specialty therapeutics, particularly in oncology and immunology. The company's flagship asset is Opdivo (nivolumab), a PD-1 checkpoint inhibitor co-developed with Bristol Myers Squibb, which generates substantial royalty revenue from global sales outside Japan while Ono retains full commercial rights domestically. The stock trades on Japan-specific healthcare dynamics, patent exclusivity timelines, and pipeline progression in autoimmune diseases.
Ono operates a hybrid model combining direct commercialization in Japan with strategic licensing partnerships. The company earns high-margin revenue from Opdivo sales in the Japanese market where it holds exclusive rights, while collecting royalties on BMS's global Opdivo sales (estimated 2-4% royalty rate on ex-Japan revenue). Pricing power derives from Japan's National Health Insurance reimbursement system, though biennial price cuts (typically 5-10%) erode margins over time. Competitive advantage lies in established Japanese commercial infrastructure, strong relationships with key opinion leaders in oncology, and a focused R&D pipeline targeting unmet needs in autoimmune diseases where biologics command premium pricing.
Opdivo sales trajectory in Japan - quarterly prescription data and market share versus Merck's Keytruda in key oncology indications (lung, gastric, renal cell carcinoma)
Pipeline readouts for ONO-4578 (prostaglandin receptor antagonist for autoimmune diseases) and other mid-stage assets - Phase 2/3 data releases drive significant volatility
Japanese drug pricing policy changes - biennial National Health Insurance price revisions directly impact revenue (next major revision April 2026)
Bristol Myers Squibb's global Opdivo performance - quarterly BMS earnings affect royalty revenue expectations
Yen exchange rate movements - royalty revenue denominated in USD creates FX sensitivity
Opdivo patent cliff approaching 2028-2030 in major markets - composition of matter patents expire, opening door to biosimilar competition that could erode 50%+ of current revenue base without successful pipeline replacement
Japan's aging demographics and fiscal pressures driving aggressive drug pricing reforms - government targeting 10-15% cumulative price reductions through 2030 to control healthcare spending, structurally compressing margins
Increasing competition in PD-1/PD-L1 space from next-generation immuno-oncology combinations - Keytruda dominance and emerging bispecific antibodies threaten Opdivo market share
Merck's Keytruda has captured majority global market share in PD-1 inhibitors (estimated 60%+ versus Opdivo's 25%) with superior clinical data in first-line lung cancer - ongoing share loss risk in Japan
Pipeline dependency on early-stage assets with binary clinical risk - limited late-stage diversification beyond Opdivo franchise creates concentration risk if Phase 2/3 programs fail
Minimal financial risk given conservative capital structure and strong cash generation (FCF yield appears inflated due to likely data error, but company generates substantial positive FCF)
Pension obligations typical for Japanese corporations could create modest liability volatility with interest rate movements, though not material relative to market cap
low - Pharmaceutical demand is largely non-discretionary and insulated from economic cycles. Oncology treatments proceed regardless of GDP growth, and Japan's universal healthcare system ensures patient access. However, government budget pressures during recessions can accelerate drug price cut initiatives, creating indirect cyclical exposure through reimbursement policy.
Rising rates have modest negative impact through two channels: (1) higher discount rates compress valuation multiples for long-duration pharma cash flows, particularly affecting stocks trading on pipeline optionality, and (2) stronger yen (typical rate correlation) reduces yen-translated value of USD-denominated royalty revenue from BMS. Financing costs are minimal given low debt levels (0.16x D/E) and substantial cash generation.
Minimal - Ono operates with fortress balance sheet (3.02x current ratio, negligible debt) and does not rely on credit markets for operations. Customer credit risk is negligible as revenue comes primarily from Japanese hospitals/pharmacies with government-backed reimbursement and from BMS royalties (investment-grade counterparty).
value - Stock trades at modest multiples (2.4x P/S, 10.1x EV/EBITDA) reflecting mature product portfolio and patent cliff concerns, attracting investors seeking stable cash flow generation and potential pipeline optionality at reasonable valuation. Recent 65% one-year return suggests momentum element, but core appeal is defensive healthcare exposure with Japan-specific dynamics. Not a growth story given -3.1% revenue decline, but cash generation (strong FCF) and low leverage appeal to quality-focused value investors.
moderate - Pharmaceutical stocks exhibit lower volatility than broader market (typical beta 0.6-0.8) due to non-cyclical demand, but binary clinical trial outcomes and patent cliff concerns create episodic volatility spikes. Japan-listed ADR structure adds liquidity constraints and FX volatility. Recent strong performance (44% six-month return) suggests elevated momentum-driven volatility above historical norms.
